Results 31 to 40 of about 19,727 (209)

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Journal of Transplantation, 2018
Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral
Sourabh Sharma, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, Ananth Rao   +4 more
doaj   +1 more source

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea [PDF]

Clinical and Molecular Hepatology, 2015
Background/AimsThe previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions.
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim   +5 more
doaj   +1 more source

Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) micro‐elimination faces challenges from fragmented care pathways, particularly in high‐prevalence regions with complex genotypes and socioeconomic barriers. This study evaluated a simplified ‘Test and Treat’ (TNT) strategy to enhance in‐hospital HCV micro‐elimination by reducing delays and improving linkage to care ...
You C, Diao Y, Tang J, Tang J, Deng W, Zheng C, Liao D, Song D, Wang J, Pu Y.   +9 more
europepmc   +2 more sources

Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form

Future Journal of Pharmaceutical Sciences, 2018
Objective: A simple, specific, accurate and economic reverse phase liquid chromatographic method was developed for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and tablet dosage form.
S.K. Mastanamma, S.K. Chandini, S.K. Reehana, P. Saidulu   +3 more
doaj   +1 more source

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.

PLoS ONE, 2021
BackgroundDirect-acting antiviral (DAA) drugs have been effective in the treatment of chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and efficacy in American Indian or Alaska Native people.
Lisa Townshend-Bulson, Elena Roik, Youssef Barbour, Dana J T Bruden, Chriss E Homan, Hannah G F Espera, Timothy J Stevenson, Annette M Hewitt, Wileina Rhodes, James E Gove, Julia N Plotnik, Mary M Snowball, John McGilvray, Brenna C Simons, Janet M Johnston, Brian J McMahon   +15 more
doaj   +1 more source

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

The Lancet Microbe, 2020
Summary: Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy.
Catherine A Chappell, MD, Kimberly K Scarsi, PharmD, Brian J Kirby, PhD, Vithika Suri, MSc, Anuj Gaggar, MD, Debra L Bogen, ProfMD, Ingrid S Macio, PA, Leslie A Meyn, PhD, Katherine E Bunge, MD, Elizabeth E Krans, MD, Sharon L Hillier, ProfPhD   +10 more
doaj   +1 more source

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis [PDF]

The Korean Journal of Internal Medicine, 2020
Background/Aims New direct-acting antivirals have shown surprising success in the treatment of hepatitis C, not only in the general population, but also in difficult-to-treat cohorts.
Hee Yeon Seo, Myeong-Sook Seo, Sun-Young Yoon, Jong Wook Choi, Soon Young Ko   +4 more
doaj   +1 more source

Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]

, 2017
BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Farinati, Fabio, Ferrarese, Alberto, Forton, Dm, Franceschet, E, Gambato, M, Germani, Giacomo, Mescoli, Claudia, Romano, Antonietta, Rugge, Massimo, Russo, FRANCESCO PAOLO, Senzolo, Marco, Shalaby, S, Vitale, A, Zanetto, Alberto   +16 more
core   +1 more source

Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus

Viruses, 2021
Dengue virus (DENV) is a flavivirus associated with clinical manifestations ranging in severity from self-limiting dengue fever, to the potentially life threatening condition, severe dengue.
Evelyn J. Franco, Camilly P. Pires de Mello, Ashley N. Brown   +2 more
doaj   +1 more source